Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women

Background The impact of the prophylactic vaccine against human papillomavirus (HPV) types 6, 11, 16, and 18 (HPV6/11/16/18) on all HPV-associated genital disease was investigated in a population that approximates sexually naive women in that they were 'negative to 14 HPV types' and in a m...

Full description

Autores:

Tipo de recurso:

Fecha de publicación:

2010

Institución:

Universidad del Rosario

Repositorio:

Repositorio EdocUR - U. Rosario

Idioma:

eng

OAI Identifier:

oai:repository.urosario.edu.co:10336/22479

Acceso en línea:

https://doi.org/10.1093/jnci/djp534
https://repository.urosario.edu.co/handle/10336/22479

Palabra clave:

Aluminum hydroxyphosphate sulfate
Immunological adjuvant
Placebo
Silgard
Unclassified drug
Wart virus vaccine
Adenocarcinoma in situ
Adjuvant therapy
Adolescent
Adult
Article
Carcinoma in situ
Clinical trial
Colposcopy
Condyloma acuminatum
Controlled clinical trial
Controlled study
Double blind procedure
Drug efficacy
Female
Follow up
Gynecologic disease
Human
Human papillomavirus type 11
Human papillomavirus type 16
Human papillomavirus type 18
Human papillomavirus type 6
Human tissue
Major clinical study
Multicenter study
Papanicolaou test
Population exposure
Priority journal
Randomized controlled trial
Risk reduction
Uterine cervix carcinoma in situ
Uterine cervix cytology
Vaccination
Vagina cancer
Vagina intraepithelial neoplasia
Vulva cancer
Vulva intraepithelial neoplasia
Adolescent
Adult
Alphapapillomavirus
Cervical intraepithelial neoplasia
Female
Human papillomavirus 11
Human papillomavirus 16
Human papillomavirus 18
Human papillomavirus 6
Humans
Kaplan-meiers estimate
Papillomavirus infections
Papillomavirus vaccines
Sexual partners
Sexually transmitted diseases
Tumor virus infections
Uterine cervical neoplasms
Vaginal smears
World health
Young adult
female
Genital diseases

Rights

License

Abierto (Texto Completo)